awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34334943-4BA805FC-F4D6-4447-BBE0-2C3E5BC9C7DB
Q34334943-4BA805FC-F4D6-4447-BBE0-2C3E5BC9C7DB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34334943-4BA805FC-F4D6-4447-BBE0-2C3E5BC9C7DB
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
P2860
Q34334943-4BA805FC-F4D6-4447-BBE0-2C3E5BC9C7DB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34334943-4BA805FC-F4D6-4447-BBE0-2C3E5BC9C7DB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9d2b29c9ca629829befeac2eec518bb9d384c063
P2860
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.